Oral asciminib (ABL001) vs bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who received ≥ 2 prior tyrosine kinase inhibitors (TKIs): A multicenter, open-label, randomized, phase 3 study Meeting Abstract
| Authors: | Mauro, M.; Boquimpani, C.; Minami, Y.; Réa, D.; Kemp, C.; Hsu Schmitz, S. F.; Gopalakrishna, P.; Hochhaus, A. |
| Abstract Title: | Oral asciminib (ABL001) vs bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who received ≥ 2 prior tyrosine kinase inhibitors (TKIs): A multicenter, open-label, randomized, phase 3 study |
| Meeting Title: | 5th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 17 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Sep 13-16 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-09-01 |
| Start Page: | S315 |
| End Page: | S316 |
| Language: | English |
| ACCESSION: | 124936380 |
| DOI: | 10.1016/j.clml.2017.07.116 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abtract: CML-165 -- Accession Number: 124936380 -- Entry Date: In Process -- Revision Date: 20170904 -- Publication Type: Article -- Supplement Title: Sep2017 Supplement 2 -- Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101525386. -- Source: cin20 |
